



UNIVERSITY OF LEEDS

This is a repository copy of '*The start of another infection prevention learning curve: reducing healthcare-associated Gram-negative bloodstream infections*' Reply.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/140703/>

Version: Accepted Version

---

**Article:**

Wilcox, MH [orcid.org/0000-0002-4565-2868](http://orcid.org/0000-0002-4565-2868) (2018) 'The start of another infection prevention learning curve: reducing healthcare-associated Gram-negative bloodstream infections' Reply. *Journal of Hospital Infection*, 99 (4). pp. 434-435. ISSN 0195-6701

<https://doi.org/10.1016/j.jhin.2018.03.026>

---

© 2018 The Healthcare Infection Society. Published by Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license  
<http://creativecommons.org/licenses/by-nc-nd/4.0/>.

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Reply to Joseph et al.****Mark H. Wilcox**

Consultant / Head of Microbiology Research and Development, Leeds Teaching Hospitals  
NHS Trust;

Professor of Medical Microbiology & Sir Edward Brotherton Chair of Bacteriology, University  
of Leeds;

Lead on *C. difficile* infection, Public Health England;

Medical Advisor to National Infection Prevention & Control Lead, NHS Improvement.

Corresponding author:

Professor Mark H. Wilcox

Microbiology,  
Old Medical School,  
Leeds General Infirmary,  
Leeds LS1 3EX,  
W. Yorks., UK.

[mark.wilcox@nhs.net](mailto:mark.wilcox@nhs.net)

Tel +44 113 392 6818

Fax +44 113 392 2696

Joseph et al comment about the rate of multidrug resistant (MDR) Gram-negative bloodstream infections (GNBSI) rates in Nottingham decreasing between 2007 and 2016.<sup>1</sup> I agree that the overall burden of GNBSIs in England is dominated by relatively susceptible rather than MDR strains; my review did not state the opposite.<sup>2</sup> When referring to susceptible GNBSIs, Joseph et al comment that ‘prevention and control measures as yet remained undefined’ and cite a recent study to support their statement.<sup>3</sup> Actually, the latter study was about MDR bacteria. It remains plausible that antibiotic exposure, which I highlighted as an important potential intervention to achieve the ambition to reduce healthcare-associated (HA) GNBSI in England, can affect the risk of infection caused by both MDR and relatively susceptible strains.<sup>4</sup>

I agree with Joseph and colleagues that it remains unclear about whether or not currently recognised factors associated with GNBSIs are truly causal in nature.<sup>1</sup> Nevertheless, these are important potential starting points to determine how we can reduce patient risk for GNBSI. The ambition to reduce (HA) GNBSIs is a patient safety issue, and so opportunities to intervene should not be lost, as stated in recent national guidance.<sup>5</sup> This is particularly pertinent as we learn more about how best to reverse the recent epidemiological trends of infections that are associated with excess morbidity, mortality and hospital length of stay.<sup>6</sup> For this reason, I believe that the presence of a healthcare associated ‘risk factor’ is enough to assume that the GNBSI is HA. It is not true, as stated by Joseph et al, that there is currently no guidance available to start to tackle (antibiotic susceptible) GNBSIs reduction targets. Multiple potential interventions are available.<sup>5</sup> The challenge is to ensure these are optimally implemented by IPC teams and to monitor available surveillance data (and local audit data) to determine their effectiveness.

#### **Conflict of interest statement**

None.

#### **Funding sources**

None.

## References

1. Joseph A, Weston V, Boswell T. *Escherichia coli* bloodstream infections associated with healthcare exposure: A major contributor with modifiable risk factors or a confounding association? J Hosp Infect ????.
2. Wilcox MH. The start of another infection prevention learning curve: reducing healthcare associated Gram-negative blood stream infections. J Hosp Infect 2017;97:205-206.
3. Thaden JT, Li Y, Ruffin F, Maskarinec SA, Hill-Rorie JM, Wanda LC, Reed SD, Fowler VG. Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections. Antimicrobial agents and chemotherapy. 2017 Mar 1;61(3):e01709-16.
4. Hill DA, Hoffmann C, Abt MC, Du Y, Kobuley D, Kirn TJ, Bushman FD, Artis D. Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. Mucosal Immunol 2010;3:148-58.
5. NHS Improvement. Preventing healthcare associated Gram-negative bacterial bloodstream infections. Available at: <https://improvement.nhs.uk/resources/preventing-gram-negative-bloodstream-infections/> Last accessed 18 March 2018.
6. Naylor NR, Pouwels KB, Hope R, Green N, Henderson KL, Knight GM, Atun R, Robotham JV, Deeny S. A National Estimate of the Health and Cost Burden of *Escherichia coli* Bacteraemia in the Hospital Setting: The Importance of Antibiotic Resistance. bioRxiv 2017. doi: <https://doi.org/10.1101/153775>